As shown in Table 3, the synergistic effects of TH-302 combined with Chk1 inhibitors were observed in the p53-deficient HeLa cell line but not in p53-proficient H460 or p53 heterozygous DU145 human tumor cell lines. This evidence concerns the gene TP53 and neoplasm.